Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension

References

• Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S55-66
   PubMed Web of Science ®Google Scholar
• Stringham R, Shah NR. Pulmonary arterial hypertension: an update on diagnosis and treatment. Am Fam Physician 2010;82:370-7
   Google Scholar
• Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30
   PubMed Web of Science ®Google Scholar
• Barst RJ. Pulmonary hypertension: past, present and future. Ann Thorac Med 2008;3:1-4
   Google Scholar
• D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-63
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164-72
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619
   PubMed Web of Science ®Google Scholar
• Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-28
   PubMed Web of Science ®Google Scholar
• Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S78-84
   PubMed Web of Science ®Google Scholar
• Houtchens J, Martin D, Klinger JR. Diagnosis and management of pulmonary arterial hypertension. Pulm Med 2011;2011:845-864
   Google Scholar
• Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Eng J Med 2009;361:1864-71
   PubMed Web of Science ®Google Scholar
• Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982–2006. Eur Respir J 2007;30:1103-10
   PubMed Web of Science ®Google Scholar
• Frishman WH. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev 2007;15:257-63
   PubMedGoogle Scholar
• Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: A review of literature. J Behav Med 2008;31:213-24
   PubMed Web of Science ®Google Scholar
• Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009;15:e22-33
   PubMed Web of Science ®Google Scholar
• Adcirca®. Once-daily Adcirca (tadalafil) tablets for the treatment of PAH. Indianapolis, IN: United Therapeutics Corporation, 2010. www.adcirca.com. Accessed January 31, 2012
   Google Scholar
• Revatio®. Revatio Start with Confidence. New York City: Pfizer Inc, 2009. www.revatio.com. Accessed January 31, 2012
   Google Scholar
• McDonald RC. Managing the intersection of medical and pharmacy benefits. J Manag Care Pharm 2008;14(4 Suppl):S7-11
   Google Scholar
• Stern D, Reissman D. Specialty pharmacy cost management strategies of private health care payers. J Manag Care Pharm 2006;12:736-44
   Google Scholar
• Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Safety 2006;15:565-74
   PubMed Web of Science ®Google Scholar
• Fishman PA, Goodman MJ, Hornbrook MC, et al. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care 2003;41:84-99
   PubMed Web of Science ®Google Scholar
• Cramer JA. Effect of partial compliance on cardiovascular medication effectiveness. Heart 2002;88:203-6
   PubMed Web of Science ®Google Scholar
• O'Brien MK, Petrie K, Raeburn J. Adherence to medication regimens: updating a complex medical issue. Med Care Rev 1992;49:435-54
   PubMedGoogle Scholar
• Liu Y, Yang M, Chao J, et al. Greater refill adherence to adalimumab therapy for patients using specialty versus retail pharmacies. Adv Ther 2010;27:523-32
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002;24:302-16
   PubMed Web of Science ®Google Scholar
• Cole JA, Norman H, Weatherby LB, et al. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes. Pharmacotherapy 2006;26:1157-64
   PubMed Web of Science ®Google Scholar
• Gibson TB, Mark TL, McGuigan KA, et al. The effects of prescription drug copayments on statin adherence. Am J Manag Care 2006;12:509-17
   PubMed Web of Science ®Google Scholar
• Kessler RC, Cantrell CR, Berglund P, et al. The effects of copayments on medication adherence during the first two years of prescription drug treatment. J Occup Environ Med 2007;49:597-609
   PubMed Web of Science ®Google Scholar
• Philipson TJ, Mozaffari E, Maclean JR. Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome. Am J Manag Care 2010;16:290-7
   PubMed Web of Science ®Google Scholar
• Taira DA, Wong KS, Frech-Tamas F, et al. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care 2006;12:678-83
   PubMed Web of Science ®Google Scholar
• Gleason PP, Starner CI, Gunderson BW, et al. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm 2009;15:648-58
   PubMed Web of Science ®Google Scholar